HomeCompareSPHRF vs MRK

SPHRF vs MRK: Dividend Comparison 2026

SPHRF yields 606.06% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SPHRF wins by $280371.11M in total portfolio value
10 years
SPHRF
SPHRF
● Live price
606.06%
Share price
$0.33
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$280371.17M
Annual income
$211,667,981,687.60
Full SPHRF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — SPHRF vs MRK

📍 SPHRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSPHRFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SPHRF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SPHRF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SPHRF
Annual income on $10K today (after 15% tax)
$51,515.15/yr
After 10yr DRIP, annual income (after tax)
$179,917,784,434.46/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, SPHRF beats the other by $179,917,776,106.05/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SPHRF + MRK for your $10,000?

SPHRF: 50%MRK: 50%
100% MRK50/50100% SPHRF
Portfolio after 10yr
$140185.61M
Annual income
$105,833,995,742.87/yr
Blended yield
75.50%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

SPHRF
No analyst data
Altman Z
11.2
Piotroski
3/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SPHRF buys
0
MRK buys
0
No recent congressional trades found for SPHRF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSPHRFMRK
Forward yield606.06%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$280371.17M$56.8K
Annual income after 10y$211,667,981,687.60$9,798.13
Total dividends collected$274648.71M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SPHRF vs MRK ($10,000, DRIP)

YearSPHRF PortfolioSPHRF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$71,306$60,606.06$11,206$366.19+$60.1KSPHRF
2$480,183$403,885.93$12,650$502.35+$467.5KSPHRF
3$3,055,680$2,541,883.57$14,407$694.19+$3.04MSPHRF
4$18,386,820$15,117,242.14$16,585$967.82+$18.37MSPHRF
5$104,687,331$85,013,433.96$19,342$1,363.89+$104.67MSPHRF
6$564,382,839$452,367,394.46$22,913$1,947.19+$564.36MSPHRF
7$2,883,114,581$2,279,224,943.60$27,662$2,823.89+$2883.09MSPHRF
8$13,966,501,456$10,881,568,854.67$34,159$4,173.35+$13966.47MSPHRF
9$64,208,586,900$49,264,430,341.75$43,337$6,308.80+$64208.54MSPHRF
10$280,371,169,670$211,667,981,687.60$56,776$9,798.13+$280371.11MSPHRF

SPHRF vs MRK: Complete Analysis 2026

SPHRFStock

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. It offers VivaGel, a non-antibiotic therapy for the treatment and prevention of bacterial vaginosis. The company also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, it develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase 2 clinical trials, DEP cabazitaxel that is in Phase 2 clinical trial, DEP gemcitabine that is in a Phase 1/2 clinical trials, and DEP irinotecan that is in Phase 2 clinical trials for the treatment of cancer; DEP radiotheranostics for cancer treatment and diagnosis; DEP Antibody Drug Conjugates; DEP HER-2 ADC; DEP non-oncology candidates; and DEP AZD0466, which is in Phase 1/2 clinical trials to treat haematological malignancies. The company was founded in 1996 and is headquartered in Abbotsford, Australia.

Full SPHRF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this SPHRF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SPHRF vs SCHDSPHRF vs JEPISPHRF vs OSPHRF vs KOSPHRF vs MAINSPHRF vs JNJSPHRF vs ABBVSPHRF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.